{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:18:30Z","timestamp":1790709510831,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["13,55,58,61"],"award-info":[{"award-number":["13,55,58,61"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["14,21,23"],"award-info":[{"award-number":["14,21,23"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["41\u201344,53,54"],"award-info":[{"award-number":["41\u201344,53,54"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["55,58,61"],"award-info":[{"award-number":["55,58,61"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["56,57,62"],"award-info":[{"award-number":["56,57,62"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["597\/601"],"award-info":[{"award-number":["597\/601"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","award":["NCT05239143"],"award-info":[{"award-number":["NCT05239143"]}],"id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008355","name":"Solid Wood Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["41\u201344"],"award-info":[{"award-number":["41\u201344"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["V600E"],"award-info":[{"award-number":["V600E"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA233084"],"award-info":[{"award-number":["CA233084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA97098"],"award-info":[{"award-number":["CA97098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["KLF4"],"award-info":[{"award-number":["KLF4"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["GO-203"],"award-info":[{"award-number":["GO-203"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.canlet.2023.216116","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T14:17:14Z","timestamp":1678025834000},"page":"216116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer"],"prefix":"10.1016","volume":"559","author":[{"given":"Yoshihiro","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Haratake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Daimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atrayee","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yozo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-8888","authenticated-orcid":false,"given":"Donald W.","family":"Kufe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216116_bib1","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","article-title":"Precision oncology in metastatic colorectal cancer - from biology to medicine","volume":"18","author":"Di Nicolantonio","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.601722","article-title":"Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer","volume":"11","author":"Grassi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3346\/jkms.2017.32.1.38","article-title":"BRAF-mutated colorectal cancer exhibits distinct clinicopathological features from wild-type BRAF-expressing cancer independent of the microsatellite instability status","volume":"32","author":"Jang","year":"2017","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.canlet.2023.216116_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/modpathol.3800618","article-title":"Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis","volume":"19","author":"Ogino","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2023.216116_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216116_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216116_bib8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41388-017-0063-5","article-title":"BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines","volume":"37","author":"Herr","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216116_bib9","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2023.216116_bib10","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/1078-0432.CCR-11-1446","article-title":"Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents","volume":"19","author":"Mao","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216116_bib13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/carcin\/bgaa082","article-title":"MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment","volume":"41","author":"Kufe","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2023.216116_bib14","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.3390\/cancers14194805","article-title":"Emergence of MUC1 in mammals for adaptation of barrier epithelia","volume":"14","author":"Kufe","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216116_bib15","article-title":"Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells","volume":"8","author":"Kufe","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.canlet.2023.216116_bib16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41388-017-0096-9","article-title":"MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells","volume":"37","author":"Rajabi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216116_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.gde.2021.06.003","article-title":"The transcription factor code in iPSC reprogramming","volume":"70","author":"Deng","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2023.216116_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2010.04.037","article-title":"Chromatin-remodeling components of the BAF complex facilitate reprogramming","volume":"141","author":"Singhal","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2016.12.016","article-title":"Cooperative binding of transcription factors orchestrates reprogramming","volume":"168","author":"Chronis","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib20","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899165","article-title":"Heterochromatin loosening by the Oct4 linker region facilitates Klf4 binding and iPSC reprogramming","volume":"39","author":"Chen","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2023.216116_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/0008-5472.CAN-20-2588","article-title":"MUC1-C activates the BAF (mSWI\/SNF) complex in prostate cancer stem cells","volume":"81","author":"Hagiwara","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib22","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1038\/s41388-021-01899-y","article-title":"MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells","volume":"40","author":"Hagiwara","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216116_bib23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1541-7786.MCR-21-0672","article-title":"MUC1-C dictates JUN and BAF-mediated chromatin remodeling at enhancer signatures in cancer stem cells","volume":"20","author":"Bhattacharya","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137112","article-title":"MUC1-C drives stemness in progression of colitis to colorectal cancer","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2023.216116_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2391670","article-title":"Prognostic and clinicopathological significance of MUC family members in colorectal cancer: a systematic review and meta-analysis","volume":"2019","author":"Li","year":"2019","journal-title":"Gastroenterol Res. Pract."},{"key":"10.1016\/j.canlet.2023.216116_bib26","first-page":"1909","article-title":"Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis","volume":"6","author":"Biemer-Huttmann","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1541-7786.MCR-22-0165","article-title":"Dependence on the MUC1-C oncoprotein in classic, variant and non-neuroendocrine small cell lung cancer","volume":"20","author":"Fushimi","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib28","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.3390\/cancers14112580","article-title":"Targeting MUC1-C suppresses chronic activation of cytosolic nucleotide receptors and STING in triple-negative breast cancer","volume":"14","author":"Yamashita","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216116_bib29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-019-14219-6","article-title":"MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer","volume":"11","author":"Yasumizu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216116_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.canlet.2023.216116_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/s12885-019-6175-2","article-title":"Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting","volume":"19","author":"Carroll","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2023.216116_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216116_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/1747-1028-5-11","article-title":"An overview of Cdk1-controlled targets and processes","volume":"5","author":"Enserink","year":"2010","journal-title":"Cell Div."},{"key":"10.1016\/j.canlet.2023.216116_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031293","article-title":"Cell cycle-dependent transcription: the cyclin dependent kinase CDK1 is a direct regulator of basal transcription machineries","volume":"23","author":"Enserink","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2023.216116_bib36","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/0008-5472.CAN-19-1034","article-title":"MUC1-C activates the NuRD complex to drive dedifferentiation of triple-negative breast cancer cells","volume":"79","author":"Hata","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib37","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2023.216116_bib38","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1021\/acs.jcim.0c00307","article-title":"Structural determinants of phosphopeptide binding to the N-terminal Src homology 2 domain of the SHP2 phosphatase","volume":"60","author":"Anselmi","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.canlet.2023.216116_bib39","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.csbj.2021.04.040","article-title":"Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network","volume":"19","author":"Marasco","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.canlet.2023.216116_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2023.216116_bib41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fonc.2019.00626","article-title":"Stem cell plasticity and dormancy in the development of cancer therapy resistance","volume":"9","author":"De Angelis","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib42","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216116_bib43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib45","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-14-3000","article-title":"Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation","volume":"21","author":"Hasegawa","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib46","article-title":"MUC1-C dictates PBRM1-mediated chronic induction of interferon signaling, DNA damage resistance and immunosuppression in triple-negative breast cancer","author":"Yamashita","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib47","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/0008-5472.CAN-15-1804","article-title":"Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas","volume":"76","author":"Bouillez","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/0008-5472.CAN-13-3686","article-title":"B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells","volume":"75","author":"Herr","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1073\/pnas.1508535113","article-title":"Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2023.216116_bib51","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.celrep.2015.08.037","article-title":"PTPN11 Is a central node in intrinsic and acquired cresistance to targeted cancer drugs","volume":"12","author":"Prahallad","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2023.216116_bib52","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13402-022-00698-1","article-title":"A comprehensive review of SHP2 and its role in cancer","volume":"45","author":"Asmamaw","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2023.216116_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2023.216116_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4161\/cbt.22634","article-title":"Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells","volume":"14","author":"Uchida","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2023.216116_bib56","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/1541-7786.MCR-12-0668","article-title":"Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer","volume":"11","author":"Kharbanda","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib57","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-13-3168","article-title":"Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells","volume":"20","author":"Kharbanda","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib58","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1111\/cas.14574","article-title":"Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma","volume":"111","author":"Shigeta","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216116_bib59","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-19-0311","article-title":"Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization","volume":"25","author":"Schirripa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216116_bib60","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41388-017-0035-9","article-title":"Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers","volume":"37","author":"Kotani","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216116_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1535-6108(04)00020-0","article-title":"Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents","volume":"5","author":"Ren","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216116_bib62","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/onc.2013.308","article-title":"Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells","volume":"33","author":"Raina","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216116_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99880","article-title":"Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate","volume":"3","author":"Panchamoorthy","year":"2018","journal-title":"JCI Insight"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:07:33Z","timestamp":1759594053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":63,"alternative-id":["S0304383523000678"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216116","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216116"}}